Clinical calculator summary
Original 2011 Gangat DIPSS-Plus
Clinical calculator summary
Original 2011 Gangat DIPSS-Plus
A four-part additive prognostic model combining DIPSS category with platelet count, transfusion need, and karyotype.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the original DIPSS-Plus score and historical primary-myelofibrosis risk group.
- Population:
- Patients with confirmed primary myelofibrosis assessed at any disease time point in the original model context.
- Factors:
- Baseline DIPSS category, Platelets below 100 x 10^9/L, Red-cell transfusion need, Unfavorable karyotype
- Reference:
- Gangat et al. J Clin Oncol. 2011;29(4):392-397. doi:10.1200/JCO.2010.32.2446.
Pin your most used calculators here by clicking the star in the dropdown.
DIPSS-Plus (Myelofibrosis)
x 10^9/L
Clinical Context & Background
This calculator reproduces the original 2011 DIPSS-Plus model. It combines the baseline DIPSS category with raw platelet count, red-cell transfusion need, and unfavorable karyotype.
Unfavorable karyotype means a complex karyotype or one or two abnormalities including +8, -7/7q-, i(17q), inv(3), -5/5q-, 12p-, or an 11q23 rearrangement. Use for confirmed primary myelofibrosis at any disease time point. Do not apply it to post-polycythemia-vera myelofibrosis, post-essential-thrombocythemia myelofibrosis, prefibrotic myelofibrosis, or anemia caused by treatment toxicity. Historical survival observations are not individualized predictions, transplant-eligibility decisions, or treatment recommendations.
Formula Logic
Original 2011 DIPSS-Plus = DIPSS category points (Low 0, Intermediate-1 1, Intermediate-2 2, High 3) + 1 when platelets are <100 x 10^9/L + 1 when red-cell transfusion is required + 1 for unfavorable karyotype.Reference Data
| Total Score | Original Risk Group | Historical Median Survival |
|---|---|---|
| 0 | Low | 15.4 years |
| 1 | Intermediate-1 | 6.5 years |
| 2 - 3 | Intermediate-2 | 2.9 years |
| 4 - 6 | High | 1.3 years |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use in confirmed primary myelofibrosis at any disease time point.
- Use unrounded platelet count and clinician-confirmed transfusion and cytogenetic status.
How To Interpret
- Add the original DIPSS category points and one point for each additional adverse factor.
- Scores 0, 1, 2-3, and 4-6 match the original four historical risk groups.
What To Do Next
- Integrate the result with current disease, molecular, symptom, treatment, transplant, and patient-specific assessment.
- Use multidisciplinary hematology review rather than this historical score alone.
Limitations
- Not for post-PV/ET or prefibrotic myelofibrosis, or treatment-toxicity anemia.
- Historical median survival values are cohort observations, not individualized predictions.
- Does not independently determine transplant eligibility or treatment.
Validated Population
Confirmed primary myelofibrosis in the original 2011 DIPSS-Plus cohort.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through visible production controls at DIPSS-Plus scores 0, 2, and 6.
- Low, Intermediate-2, and High groups rendered as expected.
- No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/myelofibrosis-dipss-plus-score-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/myelofibrosis-dipss-plus-score.json.
: Full validation test
- 384/384 original-category, raw-threshold, score-boundary, strict-input, UI/reset, trace, wording, immutability, registry, and no-panel checks passed with zero score or classification mismatches.
- Scope is the original 2011 model for confirmed primary myelofibrosis; no panel calculates DIPSS-Plus or inherits this verification status.
: Calculation and input-contract correction
- Replaced favorable numeric defaults and Object.values/Number coercion with four mandatory semantic predictors, raw finite platelet count, exact-key validation, and rejection of legacy points, malformed values, missing fields, and extra fields.
- Applied the platelet threshold to the unrounded raw value so exactly 100 x 10^9/L scores zero; preserved original DIPSS weights, additional adverse-factor weights, total range 0-6, and risk-group boundaries.
- Completed the unfavorable-karyotype definition, added all four contributions and a reconciled trace, and reframed historical median survival as a cohort observation rather than an individualized prediction, eligibility decision, or treatment recommendation.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Frequently Asked Questions
When should DIPSS-Plus (Myelofibrosis) be used?
Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.
Can DIPSS-Plus (Myelofibrosis) determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.